首页 > 市场调查报告书 > 製药

非专利药

市场调查报告书

商品编码

1347359

日本仿製药市场：2023-2028 年行业趋势、份额、规模、增长、机会和预测

Japan Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

出版日期: 2023年09月04日 | 出版商:

IMARC | 英文 115 Pages | 商品交期: 2-3个工作天内

价格

简介目录图表

市场概况：

2022年日本仿製药市场规模达到107亿美元。展望未来，IMARC集团预计到2028年市场规模将达到169亿美元，2023-2028年復合年增长率（CAGR）为7.8%。

按价值计算，日本是全球第八大仿製药市场。然而，与美国和欧洲等其他发达市场相比，仿製药在日本的渗透率传统上相对较低。从历史上看，日本仿製药的渗透率较低有几个原因。其中包括：对仿製药质量较差的看法、医生和患者对品牌药的偏好以及医生通过开低价仿製药从药品价格差异中获得的利润有限。由于日本药剂师缺乏仿製药替代权、药品审批过程的审查时间较慢以及与主要药品经销商合作的困难（其中许多经销商与主要品牌药品製造商关係密切），仿製药在日本仍然不太受欢迎。

然而，日本仿製药市场的格局在过去十年中发生了显着变化。日本政府已确定该国仿製药市场的增长对于日本的长期经济健康至关重要。日本政府认识到该国人口老龄化加剧以及品牌药品成本不断上涨，已开始改变医疗保健政策，以削减医疗费用支出。药品费用约占日本医疗总费用的五分之一，减轻这一负担已成为日本卫生行政政策的基石。用低成本仿製药替代创新产品已被确定为一种可以节省大量资金的策略。在这些倡议的推动下，仿製药的渗透率在过去几年中强劲增长。预计这将为日本国内外仿製药製造商创造巨大的机会。

这份题为《日本仿製药市场：2023-2028年行业趋势、份额、规模、增长、机会和预测》的报告对日本仿製药市场的历史、当前和未来市场趋势进行了深入分析。该研究报告是了解日本仿製药市场的驱动因素、销售趋势、处方趋势、市场结构、竞争格局、法规、主要参与者、关键药物、製造和前景的特殊工具。该报告可以为投资者、研究人员、顾问、营销策略师以及所有想要深入了解日本仿製药市场的人提供出色的指南。

回答的关键问题：

什么是仿製药？它们与品牌药有何不同？

近年来日本仿製药市场表现如何？

COVID-19 对日本仿製药市场有何影响？

与品牌药相比，仿製药的表现如何？

日本仿製药的总销售额和处方量是多少？

谁是日本仿製药市场的主要参与者？他们的表现如何？

日本仿製药市场结构如何？

日本仿製药的定价机制是怎样的？

日本仿製药的价值炼是怎样的？

日本对仿製药有哪些规定？

日本的仿製药是如何销售的？

仿製药是如何生产的？

生产仿製药对原材料和机械有哪些要求？

日本仿製药市场的驱动因素和挑战是什么？

Japan represents the world's eighth biggest market for generic drugs in terms of value. Generic drugs, however, have traditionally enjoyed a relatively lower penetration in Japan compared to other developed markets such as the United States and Europe. Historically, the lower penetration of generic drugs in japan was due to several reasons. These included - the perception of inferior quality of generic drugs, the preference of branded drugs among physicians and patients and the limited profits to be made by physicians from pharmaceutical price differentials by prescribing low priced generics. Generic drugs also remained less popular in Japan because of the lack of generic substitution rights by Japanese pharmacists, slower review times in the drug approval process and difficulties working with major pharmaceutical distributors - many of whom were closely tied to major branded drug manufacturers.

The landscape of the Japan generic drug market, however, has changed noticeably over the last decade. The Japanese government has identified growth of the country's generic drug market as imperative to Japan's long-term economic health. The Japanese government, recognizing the country's increasing aging population as well as rising costs of branded drugs has begun instituting healthcare policy changes to cut their expenditures on medical costs. Drug costs account for around a fifth of the country's total medical expenses and reducing this burden has become a cornerstone of Japan's health administration policy. Substitution of low-cost generic drugs for innovator products has been identified as a strategy where major savings are possible. Driven by these initiatives, the penetration of generics has grown robustly over the past few years. This is expected to create huge opportunities for both domestic and foreign generic manufacturers in Japan.

The report entitled "Japan Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" represents an in-depth analysis on the historical, current and future market trends in the generic drug market in Japan. This research report serves as an exceptional tool to understand the drivers, sales trends, prescription trends, market structure, competitive landscape, regulations, key players, key drugs, manufacturing and the outlook of generic drug market in Japan. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who want to gain an insight into the generic drug market in Japan.

Key Questions Answered:

What are generic drugs? How are they different from branded drugs?

How has Japan's generic drug market performed in recent years?

What has been the impact of COVID-19 on the Japan generic drug market?

How have generic drugs performed compared to branded drugs?

What were the total sales and prescriptions for generic drugs in Japan?

Who are the key players in the Japanese generic drug market? How have they performed?

What is the structure of the Japanese generic drug market?

What is the pricing mechanism of generic drugs in Japan?

What is the value chain of generic drugs in Japan?

What are the regulations for generic drugs in Japan?

How are generic drugs distributed in Japan?

How are generic drugs manufactured?

What are the raw material and machinery requirements to manufacture generic drugs?

What are the drivers and challenges in the Japanese generic drug market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Generic Drug Market - Introduction

4.1 What are Generic Drugs?
4.2 Unbranded and Branded Generic Drugs
4.3 Authorized Generic Drugs

5 Why is the Japanese Generic Drug Market So Lucrative

5.1 Blockbuster Drugs Going Off-Patent
5.2 Rising Healthcare Costs Coupled with an Increasing Ageing Population
5.3 Japan Has One of the Lowest Penetration of Generics
5.4 Incentives for Dispensing Generics
5.5 Significant Savings for Payers and Providers
5.6 Biosimilars

6 Global Generic Drug Market

6.1 Market Performance
- 6.1.1 Value Trends
- 6.1.2 Volume Trends
6.2 Market Breakup by Country
- 6.2.1 Market Breakup by Volume
- 6.2.2 Market Breakup by Value
6.3 Market Forecast
6.4 Most Prescribed Generic and Branded Drugs

7 Japan Generic Drug Market

7.1 Japan Pharmaceutical Market Performance
- 7.1.1 Value Trends
- 7.1.2 Volume Trends
- 7.1.3 Market Breakup by Type
- 7.1.4 Market Forecast
7.2 Japan Generic Drug Market Performance
- 7.2.1 Value Trends
- 7.2.2 Volume Trends
- 7.2.3 Impact of COVID-19
- 7.2.4 Market Forecast

8 SWOT Analysis

8.1 Overview
8.2 Strength
8.3 Weakness
8.4 Opportunities
8.5 Threats

9 Pricing Mechanism and Profit Margins at Various Levels of Supply Chain

10 Porter's Five Forces Analysis

10.1 Overview
10.2 Bargaining Power of Buyers
10.3 Bargaining Power of Suppliers
10.4 Degree of Competition
10.5 Threat of New Entrants
10.6 Threat of Substitutes

11 Japan Generic Drug Market- Competitive Landscape

11.1 Japan Generic Drug Market - Competitive Structure
11.2 Japan Generic Drug Market - Breakup by Key Players
11.3 Japan Generic Drug Market - Breakup by Distribution Channel

12 Japan Generic Drug Market- Value Chain Analysis

12.1 Research and Development
12.2 Manufacturing
12.3 Marketing
12.4 Distribution

13 Regulations in Japan Generics Industry

13.1 Approval Pathway of a Generic Drug in Japan
- 13.1.1 Master File Scheme for Active Ingredients
- 13.1.2 Equivalency Review
- 13.1.3 Conformity Audit
13.2 Certifications
- 13.2.1 MAH (Market Authorization Holder) License for Product Approval
- 13.2.2 FMA (Foreign Manufacturer Accredited) Certification for Product Approval
- 13.2.3 DMF (Drug Master File) Registration
- 13.2.4 GMP (Good Manufacturing Practices) Certification
- 13.2.5 Manufacturer's License

14 Japan Generic Drug Market: Key Success Factors

15 Japan Generic Drug Market: Road Blocks

16 Requirements for Setting up a Generic Drug Manufacturing Plant

16.1 Manufacturing Process
16.2 Raw Material Requirements
16.3 Raw Material Pictures
16.4 Land and Construction Requirements
16.5 Machinery and Infrastructure Requirements
16.6 Machinery Pictures
16.7 Plant Layout
16.8 Packaging Requirements
16.9 Utility Requirements
16.10 Manpower Requirements

17 Japan Generic Drug Market - Key Company Profiles

简介目录图表

List of Figures

Figure 1: Structure of the Pharmaceutical Industry
Figure 2: Classification of Generic Drugs
Figure 3: Penetration of Generic Drugs Across Various Developed Markets
Figure 4: Global: Generic Drug Market: Sales Value (in Billion US$), 2017-2022
Figure 5: Global: Generic Drug Market: Sales Volume (in Billion Units), 2017-2022
Figure 6: Global: Generic Drug Market: Sales Value Breakup by Country (in %), 2022
Figure 7: Global: Generic Drug Market: Sales Volume Breakup by Country (in %), 2022
Figure 8: Global: Generic Drug Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 9: Global: Generic Drug Market Forecast: Sales Volume (in Billion Units), 2023-2028
Figure 10: Japan: Pharmaceutical Market: Sales Value (in Billion JPY), 2017-2022
Figure 11: Japan: Pharmaceutical Market: Sales Volume (in Billion Units), 2017-2022
Figure 12: Japan: Pharmaceutical Market Forecast: Sales Value (in Billion JPY), 2023-2028
Figure 13: Japan: Pharmaceutical Market Forecast: Sales Volume (in Billion Units), 2023-2028
Figure 14: Japan: Pharmaceutical Market: Sales Volume Breakup of Branded and Generic Drugs (in %), 2017 and 2022
Figure 15: Japan: Pharmaceutical Market: Sales Value Breakup of Branded and Generic Drugs (in %), 2017 and 2022
Figure 16: Japan: Generic Drug Market: Sales Value (in Billion US$), 2017-2022
Figure 17: Japan: Generic Drug Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 18: Japan: Generic Drug Market: Sales Volume (in Billion Units), 2017-2022
Figure 19: Japan: Generic Drug Market Forecast: Sales Volume (in Billion Units), 2023-2028
Figure 20: Japan: Generic Drug Market: Breakup by Key Players (in %)
Figure 21: Japan: Generic Drug Market: Breakup by Distribution Channel (in %)
Figure 22: Japan: Generic Drug Industry: SWOT Analysis
Figure 23: Pricing Mechanism and Profit Margins at Various Levels of the Supply Chain
Figure 24: Japan: Generic Drug Industry: Porter's Five Forces Analysis
Figure 25: Japan: Generic Drug Industry: Value Chain Analysis
Figure 26: Japan: Generic Drug Manufacturing: Detailed Process Flow
Figure 27: Japan: Generic Drug Manufacturing: Raw Material Requirements
Figure 28: Japan: Generic Drug Manufacturing Plant: Proposed Plant Layout
Figure 29: Japan: Generic Drug Manufacturing: Packaging Requirements
Figure 30: Japan: Approval Pathway for a Generic Drug

List of Tables

Table 1: Japan: Sales (in Billion US$) and Patent Expiry of Major Drugs Expected to Lose Patent Protection (in Billion US$)
Table 2: Japan: History of Major Policies to Encourage the Use of Generic Drugs
Table 3: Japan: Expenses of Generic and Branded Drug Manufacturers (in %)
Table 4: Major Biosimilar Product Under Development as of March 2021
Table 5: Japan: Generic Drug Market: Key Industry Highlights, 2022 and 2028
Table 6: Global: Generics Market: Volume Performance of Top Molecules (in Million Prescriptions)
Table 7: Global: Branded Drug market: Volume Performance of Top Branded Drugs (in Million Prescriptions)
Table 8: Japan: Generic Drug Industry: Market Structure
Table 9: Generic Drug Manufacturing Plant: Machinery Costs (in US$)
Table 10: Generic Oncology Drug Manufacturing Plant: Costs Related to Salaries and Wages (in US$)
Table 11: Japan: Data Requirements for a New Generic Drug Application
Table 12: Japan: Various Bioequivalence Guidelines for Generic Drugs
Table 13: Japan: Timeline for New Generic Drug Approval
Table 14: Japan: Review Time of the Application for Partial Change Approval
Table 15: Nichi-Iko Pharmaceutical Co., Ltd: Key Financials (in US$ Million)
Table 16: Sawai Pharmaceutical Co., Ltd: Key Financials (in US$ Million)
Table 17: Towa Pharmaceutical: Key Financials (in US$ Million)
Table 18: Teva Pharmaceutical Ltd: Key Financials (in US$ Million)
Table 19: Fuji Pharma Co Ltd: Key Financials (in US$ Million)